CSIMarket
 


Purple Biotech Ltd   (PPBT)
Other Ticker:  
 

Purple Biotech Ltd 's Working Capital Ratio

PPBT's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the forth quarter 2022, Working Capital Ratio deteriorated to 4.71 below Purple Biotech Ltd 's average Working Capital Ratio.

Within Major Pharmaceutical Preparations industry 310 other companies have achieved higher Working Capital Ratio than Purple Biotech Ltd in forth quarter 2022. While Working Capital Ratio total ranking has improved so far during the IV Quarter 2022 to 1290, from total ranking in the third quarter 2022 at 1448.

Explain Working Capital Ratio
How much in Current Assets PPBT´s has?
What is the value of PPBT´s Current Liabilities?


PPBT Working Capital Ratio (Dec 31 2022)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Dec 31 2021)
IV. Quarter
Y / Y Current Liabilities Change 66.07 % 66.07 % 66.07 % 66.07 % 37.19 %
Y / Y Current Assets Change -51.77 % -51.77 % -51.77 % -51.77 % 16.32 %
Working Capital Ratio MRQ 4.71 4.71 4.71 4.71 16.22
PPBT's Total Ranking # 1290 # 1448 # 1573 # 1613 # 521
Seq. Current Liabilities Change 0 % 0 % 0 % 66.07 % 0 %
Seq. Current Assets Change 0 % 0 % 0 % -51.77 % 0 %



Working Capital Ratio forth quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 311
Healthcare Sector # 550
Overall Market # 1254


Working Capital Ratio Statistics
High Average Low
19.14 10.6 2.34
(Dec 31 2020)   (Dec 31 2019)




Financial Statements
Purple Biotech Ltd 's Current Liabilities $ 7 Millions Visit PPBT's Balance sheet
Purple Biotech Ltd 's Current Assets $ 33 Millions Visit PPBT's Balance sheet
Source of PPBT's Sales Visit PPBT's Sales by Geography


Cumulative Purple Biotech Ltd 's Working Capital Ratio

PPBT's Working Capital Ratio for the trailling 12 Months

PPBT Working Capital Ratio

(Dec 31 2022)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Dec 31 2021)
IV. Quarter
Y / Y Current Liabilities TTM Growth 66.07 % 66.07 % 66.07 % 66.07 % 37.19 %
Y / Y Current Assets TTM Growth -51.77 % -51.77 % -51.77 % -51.77 % 16.32 %
Working Capital Ratio TTM 4.71 6.64 9.04 12.12 16.22
Total Ranking TTM # 4875 # 4858 # 4832 # 4785 # 4715
Seq. Current Liabilities TTM Growth 0 % 0 % 0 % 66.07 % 0 %
Seq. Current Assets TTM Growth 0 % 0 % 0 % -51.77 % 0 %


On the trailing twelve months basis Due to unchange in Current Liabilities in the IV Quarter 2022 to $7.06 millions, cumulative Working Capital Ratio decreased to 4.71 below the Purple Biotech Ltd average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 575 other companies have achieved higher Working Capital Ratio than Purple Biotech Ltd . While Working Capital Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2022 from 4858 to 4875.

Explain Working Capital Ratio
How much in Current Assets PPBT´s has?
What is the value of PPBT´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 576
Healthcare Sector # 1195
Within the Market # 4875


trailing twelve months Working Capital Ratio Statistics
High Average Low
19.14 9.61 2.34
(Dec 31 2020)   (Dec 31 2019)




Companies with similar Working Capital Ratio in the quarter ending Dec 31 2022, within Major Pharmaceutical Preparations Industry Working Capital RatioDec 31 2022 MRQ Current AssetsDec 31 2022 MRQ Current Liabilities
Sol gel Technologies Ltd   12.93 $ 43.055  Millions$ 3.329  Millions
United Therapeutics Corporation  12.88 $ 3,380.300  Millions$ 262.400  Millions
Xenetic Biosciences Inc   12.72 $ 13.653  Millions$ 1.073  Millions
Olema Pharmaceuticals inc   12.62 $ 208.899  Millions$ 16.549  Millions
Cerevel Therapeutics Holdings Inc   12.48 $ 905.651  Millions$ 72.564  Millions
Crinetics Pharmaceuticals Inc   12.48 $ 345.852  Millions$ 27.723  Millions
Fulcrum Therapeutics Inc   12.41 $ 207.519  Millions$ 16.725  Millions
Theravance Biopharma inc   12.31 $ 353.464  Millions$ 28.715  Millions
Anebulo Pharmaceuticals Inc   12.31 $ 16.888  Millions$ 1.372  Millions
Compass Pathways Plc  12.29 $ 191.651  Millions$ 15.596  Millions
Relmada Therapeutics Inc   12.26 $ 152.870  Millions$ 12.469  Millions
Context Therapeutics Inc   12.01 $ 37.854  Millions$ 3.153  Millions
Avidity Biosciences Inc   12.00 $ 622.942  Millions$ 51.908  Millions
Aldeyra Therapeutics Inc   11.98 $ 181.023  Millions$ 15.111  Millions
Sensei Biotherapeutics Inc   11.98 $ 108.589  Millions$ 9.066  Millions
Immix Biopharma Inc   11.70 $ 14.898  Millions$ 1.273  Millions
Milestone Pharmaceuticals inc   11.70 $ 71.803  Millions$ 6.139  Millions
Ideaya Biosciences Inc   11.68 $ 370.454  Millions$ 31.718  Millions
Arcutis Biotherapeutics Inc   11.57 $ 437.406  Millions$ 37.807  Millions
Hcw Biologics Inc   11.52 $ 34.071  Millions$ 2.957  Millions
Centessa Pharmaceuticals Plc  11.42 $ 437.747  Millions$ 38.338  Millions
Vanda Pharmaceuticals Inc   11.40 $ 519.292  Millions$ 45.551  Millions
Kronos Bio Inc   11.37 $ 244.291  Millions$ 21.486  Millions
Calcimedica Inc   11.35 $ 39.670  Millions$ 3.496  Millions
Liquidia Corporation  11.34 $ 99.811  Millions$ 8.800  Millions
Verrica Pharmaceuticals Inc   11.31 $ 39.115  Millions$ 3.459  Millions
Larimar Therapeutics Inc   11.28 $ 120.739  Millions$ 10.705  Millions
Caladrius Biosciences Inc   11.26 $ 71.876  Millions$ 6.383  Millions
Chimerix Inc   11.18 $ 228.138  Millions$ 20.415  Millions
Ac Immune Sa  11.16 $ 128.094  Millions$ 11.481  Millions

Date modified: 2023-03-23T13:12:32+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com